Trump stopped a program that had been in the works and was intended to give Medicare recipients access to more than 100 generic drugs for $2 a month, according to another executive order signed on Trump's first day in his new term.

An early move by the president has raised questions about what direction his second-term policy on drug costs will take.

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.

President Donald Trump’s Day One executive order rescinding Biden-era Medicare and Medicaid price innovation programs signals sweeping changes to the drug and treatment pricing agency within the Centers for Medicare and Medicaid Services and perhaps a substantive shake-up in two of the largest federal social welfare programs.